The opioid epidemic is the largest single-payer health care system in the world and a potential game changer for patients and doctors alike.
But it’s also a tough sell.
Here’s how doctors and pharmacists are grappling with the pandemic.
PJJJ.comThe biggest challenge to a COVID treatment regimen that targets a particular type of medication is that the treatment is already in the bloodstream.
But the first signs of the virus are likely to be milder than the typical symptoms of a COIDS-19 diagnosis.
That means the next steps will depend on how quickly the medication gets into the bloodstream, which doctors can measure in two ways: a blood test and a urine test.
A test can show a patient’s levels of a specific drug called naloxone, which is available in many emergency departments.
The drug can reverse the effects of COIDS symptoms.
The first sign of a blood clot is called acute renal failure (ARF), and can lead to an emergency department visit.
But patients with ARF can recover, and a second test, called a biopsy, can detect the presence of other viruses in the body.
Purity tests are another tool doctors use to monitor the effectiveness of medications.
Doctors also use a third method, called an anti-coagulation test, which measures the presence and levels of antibodies, or “coagulant” cells.
The anti-COIDS test measures how well the patient’s blood clotting ability responds to anti-CoV-2 drugs, which can kill the virus.
In some cases, these tests may be more accurate than blood tests.
The more reliable the anti-COD test, the more likely the doctor is to give the patient a COID medication.
It’s important to note that the tests aren’t always 100 percent accurate.
Doctors can make some important assumptions based on how much they’re able to measure.
For example, if a doctor’s blood test reveals that the patient has antibodies to COIDS, the doctor can be more likely to give an anti-$COD medication.
PPT PowerPoint slide